Table 1.
Baseline demographics and characteristics
| Variable | Dulaglutide 0.75 mg (N = 280) | Liraglutide 0.9 mg (N = 137) | Placebo (N = 70) | Total (N = 487) |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Men | 228 (81) | 113 (83) | 55 (79) | 396 (81) |
| Women | 52 (19) | 24 (18) | 15 (21) | 91 (19) |
| Mean (s.d.) age, years | 57.2 (9.6) | 57.9 (10.4) | 57.7 (8.3) | 57.4 (9.6) |
| Age ≥65 years, n (%) | 68 (24) | 39 (29) | 13 (19) | 120 (25) |
| Mean (s.d.) weight, kg | 71.3 (12.5) | 70.2 (12.5) | 69.3 (11.6) | 70.7 (12.4) |
| Mean (s.d.) BMI, kg/m2 | 25.6 (3.6) | 25.5 (3.5) | 25.2 (3.2) | 25.5 (3.5) |
| Mean (s.d.) diabetes duration, years | 6.8 (5.6) | 6.3 (6.0) | 6.3 (5.1) | 6.6 (5.6) |
| Mean (s.d.) HbA1c, % | 8.15 (0.77) | 8.08 (0.89) | 8.20 (0.83) | 8.14 (0.81) |
| HbA1c >8.5%, n (%) | 89 (32) | 42 (31) | 26 (37) | 157 (32) |
| Mean (s.d.) fasting serum glucose, mmol/l | 9.4 (1.9) | 9.0 (1.9) | 9.6 (2.2) | 9.3 (1.9) |
| Pre‐study OAM therapy, n (%) | 94 (34) | 48 (35) | 22 (31) | 164 (34) |
| OAM‐naïve, n (%) | 186 (66) | 89 (65) | 48 (69) | 323 (66) |
| Mean (s.d.) HOMA2‐%β (fasting insulin) | 34.5 (19.4) | 36.9 (20.3) | 33.0 (23.5) | 34.9 (20.3) |
| Mean (s.d.) HOMA2‐%S (fasting insulin) | 99.3 (53.8) | 100.7 (52.8) | 109.1 (57.8) | 101.1 (54.1) |
All patients were from Japan. BMI, body mass index; HbA1c, glycated haemoglobin; HOMA2‐%β, updated homeostasis model assessment of β‐cell function; HOMA2‐%S, updated homeostasis model assessment of insulin sensitivity; N, number of patients in full analysis set; OAM, oral antihyperglycaemic medication; s.d., standard deviation.